Short answer
Edgewise Therapeutics, Inc. (EWTX) filed its Q3 2026 10-Q quarterly report on Nov 4, 2026 for the quarter ended Sep 30, 2026.
Q3 2026 key financials · XBRL
- Net income
- $1.2B
- +2967.6% YoY · +2134.2% QoQ
- EPS (diluted)
- $9.85
- +2692.1% YoY · +1958.5% QoQ
Source: XBRL data from the Edgewise Therapeutics, Inc. (EWTX) Q3 2026 10-Q on SEC EDGAR. USD.
Edgewise Therapeutics, Inc. Q3 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- No product revenue; net income $1,166.2M vs $40.7M loss YoY, driven by $1,348.1M Sevasemten-sale gain
- Operating margin not meaningful: operating loss $46.1M vs $46.9M YoY, while effective tax rate was 11.8%
- Best program: EDG-7500 R&D $6.8M vs $4.5M; worst: Sevasemten $2.5M vs $13.6M
- Cash, equivalents and securities $1,743.9M vs $530.1M at December 31, 2025; operating cash outflow $163.3M
- Phase 3 EDG-7500 trial planned for Q4 2026; GRAND CANYON study missed endpoints, threatening milestone payments
Risk Factors
- Newly added tax risk: Sevasemten Sale may create material cash tax obligations despite approximately $319.7 million federal NOL carryforwards
- Most materially updated regulatory risk: FDA reorganization and workforce reductions could delay reviews, inspections and clinical development timelines
- Competitive risk: Cytokinetics received Myqorzo approvals in the US, Europe and certain Asian countries during late 2025 and early 2026
- Financial risk: $1,743.9 million in cash, equivalents and marketable securities expected to fund operations for at least 12 months
- Legal compliance risk: GDPR violations can trigger fines up to €20,000,000 or 4% of worldwide annual turnover
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other Edgewise Therapeutics, Inc. quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.